Inovio Pharmaceuticals Inc. to Present at Orphan Drug Summit on Next Gen DNA Medicine for Rare Diseases

Reuters
08 Jul
Inovio Pharmaceuticals Inc. to Present at Orphan Drug <a href="https://laohu8.com/S/SMMT">Summit</a> on Next Gen DNA Medicine for Rare Diseases

Inovio Pharmaceuticals Inc. $(INO)$ is set to present at the Orphan Drug Summit in Boston, Massachusetts, on July 16. The biotechnology company will discuss the potential of next generation DNA medicine technology in rare diseases during their presentation titled "DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease."

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH25007) on July 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10